Eteplirsen

(Exondys 51®)

Exondys 51®

Drug updated on 11/13/2023

Dosage FormInjection (intravenous; 100 mg/2 mL, 500 mg/10 mL)
Drug ClassAntisense oligonucleotides
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.

Product Monograph / Prescribing Information

Document TitleYearSource
Exondys 51 (eteplirsen) Prescribing Information.2022Sarepta Therapeutics, Inc., Cambridge, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines